ASCO GU 2019: Pembrolizumab + Axitinib Improves Response, PFS, and OS in Advanced Renal Cell Carcinoma
Improved responses and prolonged survival have been seen for the first time in RCC, representing a major step forward in this disease.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.